Hemostats Market (By Product: Passive Hemostats, Combination Hemostats, Active Hemostats, Others; By Application: Plastic Surgery, Orthopedic Surgery, Trauma, Cardiovascular Surgery, General Surgery, Neurosurgery, Others; By End-User: Tactical Combat Casualty Care Centers, Hospitals & ASCs, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032

The global hemostats market size is projected to hit around USD 10.07 billion by 2032 from USD 5.08 billion in 2023 and is growing at a CAGR of 7.90% during the forecast period from 2023 to 2032.

Hemostats Market Size 2023 To 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • North America contributed the highest revenue share of 34% in 2022.
  • Asia Pacific is estimated to expand the fastest CAGR between 2023 and 2032.
  • By application, the general surgery segment has held the largest market share in 2022. 
  • By application, the cardiovascular surgery segment is anticipated to grow at a remarkable CAGR between 2023 and 2032
  • By product, the active hemostats segment has held the largest market share in 2022
  • By product, the combination hemostats segment is anticipated to grow at a remarkable CAGR between 2023 and 2032.
  • By end-user, the hospitals & ASCs segment generated the highest revenue share in 2022. 
  • By end-user, the other segment is expected to expand at the fastest CAGR over the projected period. 

Hemostats Market in the U.S. 2023 To 2032

The U.S. hemostats market size was valued at USD 1.21 billion in 2023 and is expected to reach USD 2.37 billion by 2032, poised to grow at a CAGR of 7.80% from 2023 to 2032.

U.S. Hemostats Market Size 2023 To 2032

North America has held the largest revenue share of 34% in 2022. This is due to the region's advancing healthcare, ensuring patient safety, and promoting surgical precision. It also signifies the region's role as a hub for medical device innovation, with a strong emphasis on research and development in the healthcare sector. The region is home to many leading medical device manufacturers and research institutions, fostering innovation in hemostatic products and their adoption in clinical practice. For instance, in January 2023, the U.S. Food and Drug Administration (FDA) granted the Breakthrough Device Designation for Medcura, Inc.’s LifeGel Absorbable Surgical Hemostat.

Hemostats Market Share, By Region, 2022 (%)

Asia Pacific is estimated to observe the fastest expansion. The region is growing its role in the global healthcare landscape and commitment to improving patient care, surgical outcomes, and emergency medical response, making it a vital part of the evolving healthcare ecosystem. Efforts to improve access to healthcare and reduce disparities in healthcare delivery are leading to a greater number of patients undergoing surgical procedures and trauma care, further driving the demand for the hemostats market across the region.

The hemostats market in Europe is a dynamic and evolving segment of the healthcare industry. Europe is known for its well-established healthcare systems, advanced medical technologies, and a strong focus on patient safety. Thus, the hemostats market in Europe reflects a region committed to providing advanced healthcare services with a strong emphasis on patient care, safety, and surgical precision. It continues to be a key player in the global healthcare landscape.

Hemostats Market Overview

Hemostats, also known as hemostatic forceps or arterial forceps, are surgical instruments used to control bleeding during surgical procedures or to grasp and hold tissues or blood vessels. They are designed to provide a secure and temporary method of clamping blood vessels or tissues to prevent excessive bleeding. Hemostats have a locking mechanism that allows the surgeon to maintain a constant level of pressure on the tissue or vessel, which is especially important when working in delicate or sensitive areas of the body.

The hemostats market encompasses a variety of hemostatic agents and tools designed to control bleeding in medical and surgical settings. The hemostats market is driven by various factors, including the increasing number of surgical procedures, the aging population, and ongoing advancements in medical technology. Hemostatic products are crucial in reducing blood loss during surgeries, which helps enhance patient outcomes and minimize the risk of complications. They find application in a broad range of medical disciplines, such as general surgery, orthopedics, cardiovascular surgery, and trauma care.

Growth Factors

  • As the global population continues to grow and age, there is a rising demand for various surgical procedures. Hemostats are essential tools for controlling bleeding during surgeries, and the increasing number of surgical interventions contributes to the growth of the market.
  • Healthcare professionals and medical institutions are becoming more aware of the benefits of using hemostatic agents and tools to minimize bleeding and reduce the risk of complications in surgical procedures. This awareness can lead to higher adoption rates.
  • Traumatic injuries, including accidents and emergencies, often require immediate hemostatic intervention to control bleeding. The rising incidence of trauma cases contributes to the demand for hemostatic products in emergency medicine.
  • The development of healthcare infrastructure in emerging markets and the expansion of healthcare facilities in various regions can lead to greater access to surgical procedures and, consequently, an increased demand for hemostatic products.
  • Stringent regulatory standards and quality control measures in the healthcare industry contribute to the safety and efficacy of hemostatic products, increasing confidence in their use and fostering market growth.
  • The growing trend toward minimally invasive surgical techniques has created a demand for hemostatic products that are suitable for these procedures, such as laparoscopic and robotic surgeries.

Hemostats Market Scope

Report Coverage Details
Growth Rate from 2023 to 2032 CAGR of 7.90%
Market Size in 2023 USD 5.08 Billion
Market Size by 2032 USD 10.07 Billion
Largest Market North America
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered By Product, By Application, By End-User
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Hemostats Market Dynamics


Rising number of surgical interventions

The incidence of surgical procedures continues to climb as global demographics change and populations grow. Several factors such as an aging population that involves more medical attention, a surge in the prevalence of chronic diseases requiring surgical interventions, and the development of surgical techniques and technologies. In precise, the expanding middle-class population in emerging economies has resulted in greater access to healthcare and a surge in elective surgeries. Their ability to effectively control bleeding during surgeries is paramount to ensure safe and successful procedures. Thus, these factors further drive demand across the market.

In addition, surgeons across numerous specialties rely on hemostatic devices and agents to reduce blood loss, increase surgical precision, and decrease the risk of complications. Hemostats are indispensable in a wide range of surgeries, including general surgery, orthopedics, cardiovascular surgery, and trauma care. Furthermore, as medical advancements continue, the hemostats market benefits from ongoing innovation, the development of more user-friendly products, and the integration of advanced materials and technologies. The rising demand for surgical interventions, coupled with the importance of effective bleeding control, positions the hemostats market for sustained growth and a central role in the enhancement of patient care and surgical outcomes in the years to come.


Limited access in developing regions

Thermostat agents and devices play a crucial role in modern healthcare, their reach remains limited in many parts of the world, particularly in underserved and developing regions. One primary issue is the lack of adequate healthcare infrastructure, which affects the availability of surgical services and the necessary tools, including hemostatic products. In remote and economically disadvantaged areas, healthcare facilities may be limited in number and resources, making it difficult for patients to access necessary surgical care.

Furthermore, in many developing regions, there is a shortage of trained healthcare professionals who can effectively utilize hemostatic agents and devices. This lack of expertise and awareness about these advanced medical tools can hinder their adoption. Economic factors also need to be considered. In regions with limited healthcare budgets and resources, the cost of acquiring hemostatic products may be prohibitive.

Manufacturers often face challenges in making their products affordable and accessible to healthcare institutions in these areas. The limitations in supply chain and distribution networks can further impede access to hemostatic products. Ensuring the timely and efficient delivery of these critical medical tools to remote and underserved regions can be logistically challenging.


Continued innovations in hemostats agents

The development of more advanced and effective hemostatic products plays a pivotal role in enhancing patient care, improving surgical outcomes, and reducing complications in a wide range of medical procedures. In the realm of hemostatic agents, manufacturers are continually exploring new formulations, materials, and technologies to create products that offer faster and more reliable hemostasis while minimizing the risk of adverse reactions. Innovations in these agents can lead to improved clotting efficacy and enhanced safety, ultimately benefiting patients and healthcare providers.

Moreover, the design and engineering of hemostatic devices are evolving to meet the changing demands of modern medicine. With the growth of minimally invasive surgery and the demand for precision in surgical procedures, the development of specialized devices tailored to these applications is a prominent opportunity. These innovations aim to improve usability, reduce complications, and streamline the hemostatic process. In addition, the integration of smart technologies and real-time monitoring in hemostatic products offers promising prospects.

Such advancements can provide healthcare professionals with valuable data on clotting status, wound healing, and patient vitals, enabling more informed decision-making and personalized care. As healthcare continues to advance, innovations in hemostatic agents and devices will play a vital role in ensuring that surgeries are safer, more efficient, and produce optimal patient outcomes.

Application Insights

According to the application, the general surgery segment has held highest revenue share in 2022. General surgery encompasses a broad range of procedures involving the abdomen, digestive system, and other organs. Hemostats are used to control bleeding in surgeries such as appendectomies, gallbladder removal, and hernia repairs.

The ability to achieve effective hemostasis is vital in these operations, as it contributes to reduced blood loss, shorter operating times, and decreased post-operative complications. The dominance of the general surgery segment reflects the demand for reliable, safe, and efficient solutions that healthcare providers and surgeons depend on to ensure the success and safety of general surgical interventions.

The cardiovascular surgery segment is anticipated to expand fastest over the projected period. Cardiovascular surgery is a specialized field that involves intricate procedures on the heart and blood vessels, often with minimal room for error. In heart and vascular surgeries, precise hemostasis is critical to ensure the repair or replacement of heart valves, coronary artery bypass grafting, or other procedures without complications related to bleeding.

Product Insights

In 2022, the active hemostats segment had the highest market share on the basis of the product. Active hemostats are products that contain biologically active substances or synthetic agents designed to enhance the body's natural clotting processes. These substances may include thrombin, fibrin sealants, or other clot-promoting factors. Active hemostats accelerate the clotting of blood and promote hemostasis. Thus, these factors drive demand for hemostats market across the segment.

The combination hemostats segment is anticipated to expand fastest over the projected period. This is due to these products offering a dual approach, utilizing mechanical methods to control bleeding while also promoting clot formation through the use of biologically active substances. Combination hemostats are products that incorporate both active and passive components to achieve hemostasis.

End-User Insights

In 2022, the hospitals & ASCs segment had the highest market share based on the end-user. Hospitals and ambulatory surgical centers are primary users of hemostatic agents and devices. Hemostats are extensively used in these settings across a wide range of medical specialties, including general surgery, orthopedics, cardiovascular surgery, trauma care, and more. They play a crucial role in controlling bleeding during surgical procedures and ensuring patient safety.

The others segment is anticipated to expand fastest over the projected period. The other segment usually includes other healthcare institutions, clinics, and healthcare providers that use hemostatic agents and devices to ensure that solutions are available and optimized for various clinical contexts, ultimately contributing to improved patient care, surgical outcomes, and emergency medical response. These could encompass specialty clinics, outpatient surgical facilities, dental clinics, and others.

Recent Developments

  • In July 2023, Baxter International Inc. launched PERCLOT Absorbable Hemostatic Powder in the U.S. It is a passive, absorbable hemostatic powder that is equipped to use and aimed for patients with intact coagulation to see mild bleeding.
  • In May 2023, Olympus Europa SE & Co. KG expanded its partnership with Endoclot Plus Inc. by launching 3 Endoclot products, two hemostatic agents and a submucosal injection agent, in the Europe, Middle East and Africa region. It allows Olympus to contribute to harmless treatment in gastrointestinal processes.
  • In March 2020, Ethicon announced the launch of surgical powder absorbable hemostat in Australia, New Zealand, and Thailand.

Hemostats Market Players

  • Artivion, Inc. (U.S.)
  • Baxter (U.S.)
  • Biom'up (U.S.)
  • BD (Becton, Dickinson and Company) (U.S.)
  • Integra LifeSciences (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • Medtronic (Ireland)
  • Pfizer Inc. (U.S.)
  • Stryker (U.S)

Segments Covered in the Report

By Product

  • Passive Hemostats
  • Combination Hemostats
  • Active Hemostats
  • Others

By Application

  • Plastic Surgery
  • Orthopedic Surgery
  • Trauma
  • Cardiovascular Surgery
  • General Surgery
  • Neurosurgery
  • Others

By End-User

  • Tactical Combat Casualty Care Centers
  • Hospitals & ASCs
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

Frequently Asked Questions

How big is the hemostats industry?
The global hemostats market size is expected to increase USD 10.07 billion by 2032 from USD 5.08 billion in 2023.
What is the growth rate of the hemostats industry?
The global hemostats market will register growth rate of 7.90% between 2023 and 2032.
Who are the prominent players operating in the hemostats market?
The major players operating in the hemostats market are Artivion, Inc., Baxter, Biom'up, BD (Becton, Dickinson and Company), Integra LifeSciences, Johnson & Johnson Services, Inc., Medtronic, Pfizer Inc., Stryker, amnd Others.
Which are the driving factors of the hemostats market?
The driving factors of the hemostats market are the rising number of surgical interventions and rising incidence of trauma cases .
Which region will lead the global hemostats market?
North America region will lead the global hemostats market during the forecast period 2023 to 2032.


   USD 5400
   USD 3800
   USD 2100
   USD 2100
   USD 7500


No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample